Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ipsen S.A. ADR
(OP:
IPSEY
)
30.84
+0.14 (+0.46%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Oct 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ipsen S.A. ADR
< Previous
1
2
Next >
Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure
August 03, 2022
Via
Benzinga
Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer
August 03, 2022
From
Ipsen
Via
Business Wire
Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates From Marengo’s STAR Platform Into the Clinic
August 01, 2022
From
Ipsen
Via
Business Wire
Ipsen Delivers Strong H1 2022 Results and Upgrades Its Full-Year Guidance
July 28, 2022
From
Ipsen
Via
Business Wire
Ipsen Announces U.S. FDA Priority Review for palovarotene New Drug Application in Patients With Fibrodysplasia Ossificans Progressiva Following Resubmission
June 29, 2022
From
Ipsen
Via
Business Wire
This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday
June 28, 2022
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade.
Via
Benzinga
Why Is NeuroSense Therapeutics Surging By 70%? 46 Stocks Moving In Monday's Mid-Day Session
June 27, 2022
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 87.3% to $0.6965 amid the Supreme Court overturning Roe V Wade.
Via
Benzinga
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
June 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why
June 27, 2022
Ipsen SA (OTC: IPSEY) has
Via
Benzinga
Ipsen to acquire Epizyme, expanding its portfolio in oncology
June 27, 2022
From
Epizyme, Inc.
Via
Business Wire
Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults With Neurogenic Detrusor Overactivity Due to Multiple Sclerosis or Spinal Cord Injury
June 09, 2022
From
Ipsen
Via
Business Wire
Ipsen: ASCO 2022: New Cabometyx® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer
May 26, 2022
From
Ipsen
Via
Business Wire
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
May 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer
May 03, 2022
Via
Benzinga
Ipsen: European Commission Approves Cabometyx® as a Second-Line Treatment for People Living With Radioactive Iodine-Refractory Differentiated Thyroid Cancer
May 03, 2022
From
Ipsen
Via
Business Wire
Ipsen Delivers a Strong Sales Performance in the First Quarter Of 2022
April 27, 2022
From
Ipsen
Via
Business Wire
EMA's Scientific Committee Backs Expanded Use Of Exelixis, Ipsen's Cabometyx In Thyroid Cancer
March 25, 2022
Exelixis Inc (NASDAQ: EXEL) and its partner Ipsen SA (OTC: IPSEY) have
Via
Benzinga
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy
March 15, 2022
Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus...
Via
Benzinga
A Peek Into The Markets: US Stock Futures Down Following Friday's Plunge
January 24, 2022
Pre-open movers U.S. stock futures traded lower in early pre-market trade after the Dow Jones tumbled 450 points in the previous session. Investors are awaiting earnings results...
Via
Benzinga
Ipsen's Sohonos Scores Canadian Approval For Rare Connective Tissue Disease
January 24, 2022
Health Canada has approved Ipsen SA's (OTC: IPSEY) Sohonos (palovarotene capsules) in adults and children aged eight years & above for fibrodysplasia ossificans...
Via
Benzinga
GNFT Stock Alert: 15 Things to Know About Biotech Penny Stock Genfit as Shares Go Gangbusters
December 17, 2021
Genfit (GNFT) stock is rocketing higher on Friday after the company signed an exclusive licensing agreement with Ipsen (IPSEY).
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
December 17, 2021
Good morning, investor! We're in the home stretch of the week as we tackle the biggest pre-market stock movers for Friday!
Via
InvestorPlace
Genfit Shares Rally After Ipsen Buys Rights To Its Late-Stage Kidney Disease Treatment Hopeful
December 17, 2021
Ipsen SA (OTC: IPSEY) has entered into a long-term strategic partnership to develop, manufacture, and commercialize and Genfit SA's (NASDAQ: GNFT)...
Via
Benzinga
Ipsen Stock Declines After Pulling Rare Disease Application
August 13, 2021
Ipsen (OTC: IPSEY) withdrew its US marketing application for palovarotene following discussions with the FDA indicating additional data analyses needed from two...
Via
Benzinga
Exposures
Product Safety
Exicure Stock Surges On Over $1B Option Licensing Pact With Ipsen For Rare Neurodegenerative Disorders
August 02, 2021
Ipsen SA (OTC: IPSEY) and Exicure Inc (NASDAQ: XCUR) have collaborated to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as...
Via
Benzinga
Ipsen Beefs Up Pre-Clinical Oncology Pipeline With Over $850M Deal With BAKX Therapeutics
July 27, 2021
Ipsen SA (OTC: IPSEY) and privately-held BAKX Therapeutics Inc have signed an exclusive worldwide collaboration agreement to research, develop,...
Via
Benzinga
Ipsen In-Licenses Parkinson's Candidate From IRLAB
July 15, 2021
Ipsen SA (OTC: IPSEY) and IRLAB have signed a licensing agreement, providing Ipsen exclusive rights to mesdopetam. Under the terms of the agreement,...
Via
Benzinga
Here's Why Exelixis Stock Is Dropping Today
June 28, 2021
The company reported successful clinical trial results, but investors were still disappointed.
Via
The Motley Fool
Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer
June 28, 2021
Exelixis Inc (NASDAQ: EXEL) and Ipsen (OTC: IPSEY) have announced mixed interim results from the COSMIC-312 Phase 3 trial evaluating cabozantinib (...
Via
Benzinga
3 Cheap Pharmaceutical Stocks to Grab Now
May 28, 2021
The pharmaceutical industry has been the beneficiary of significant investor attention amid the COVID-19 pandemic as society turned to its products to fight the coronavirus.
Via
Talk Markets
Exposures
COVID-19
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.